• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.伴有高级别进展的高分化胰腺神经内分泌肿瘤中的位点特异性基因组改变
Pancreas. 2018 Apr;47(4):502-510. doi: 10.1097/MPA.0000000000001030.
2
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.原发性高分化神经内分泌肿瘤及其细胞系的外显子水平比较。
Cancer Genet. 2015 Jul-Aug;208(7-8):374-81. doi: 10.1016/j.cancergen.2015.04.002. Epub 2015 Apr 14.
3
Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.染色质重塑蛋白和/或 CDKN2A 的缺失与胰腺神经内分泌肿瘤的转移和患者生存时间的减少有关。
Gastroenterology. 2018 Jun;154(8):2060-2063.e8. doi: 10.1053/j.gastro.2018.02.026. Epub 2018 Mar 2.
4
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.胰腺WHO 3级(G3)高分化神经内分泌肿瘤(WD-NET)和低分化神经内分泌癌(PD-NEC)分类的实用方法
Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.
5
Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.综合基因组和临床病理方法可区分胰腺 3 级神经内分泌肿瘤与神经内分泌癌,并确定一组具有分子重叠的肿瘤。
Mod Pathol. 2023 Mar;36(3):100065. doi: 10.1016/j.modpat.2022.100065. Epub 2023 Jan 10.
6
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.高分化3级胰腺神经内分泌肿瘤的基因组特征
Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). doi: 10.1101/mcs.a003814. Print 2019 Jun.
7
Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.异常的Menin表达是胰腺神经内分泌肿瘤发生过程中的早期事件。
Hum Pathol. 2016 Oct;56:93-100. doi: 10.1016/j.humpath.2016.06.006. Epub 2016 Jun 21.
8
Genetics of pancreatic neuroendocrine tumors: implications for the clinic.胰腺神经内分泌肿瘤的遗传学:对临床的意义
Expert Rev Gastroenterol Hepatol. 2015;9(11):1407-19. doi: 10.1586/17474124.2015.1092383. Epub 2015 Sep 28.
9
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?胰腺神经内分泌肿瘤中的端粒替代延长(ALT):是否已准备好在临床实践中投入使用?
Curr Oncol Rep. 2021 Jul 16;23(9):106. doi: 10.1007/s11912-021-01096-w.
10
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.DAXX/ATRX基因和MEN1基因是胰腺神经内分泌肿瘤的重要预后标志物。
Oncotarget. 2017 Jul 25;8(30):49796-49806. doi: 10.18632/oncotarget.17964.

引用本文的文献

1
Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms.不同器官G3级神经内分泌肿瘤中p53和Rb状态的诊断相关性:465例高级别神经内分泌肿瘤的免疫组织化学研究
Virchows Arch. 2025 May;486(5):941-950. doi: 10.1007/s00428-024-04006-0. Epub 2024 Dec 13.
2
Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors.胃肠胰神经内分泌肿瘤的耐药机制
Cancers (Basel). 2022 Dec 12;14(24):6114. doi: 10.3390/cancers14246114.
3
Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.多组学分析评估胰腺高分化神经内分泌肿瘤与导管腺癌的差异。
Int J Mol Sci. 2020 Jun 23;21(12):4470. doi: 10.3390/ijms21124470.
4
EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.EPB41L5 与低级别胰腺神经内分泌肿瘤的转移潜能相关。
Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):309-318. doi: 10.21873/cgp.20136.

本文引用的文献

1
Whole-genome landscape of pancreatic neuroendocrine tumours.胰腺神经内分泌肿瘤的全基因组图谱。
Nature. 2017 Mar 2;543(7643):65-71. doi: 10.1038/nature21063. Epub 2017 Feb 15.
2
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.胰腺神经内分泌肿瘤的转化诊断与治疗
Clin Cancer Res. 2016 Oct 15;22(20):5022-5029. doi: 10.1158/1078-0432.CCR-16-0435.
3
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.胰腺WHO 3级(G3)高分化神经内分泌肿瘤(WD-NET)和低分化神经内分泌癌(PD-NEC)分类的实用方法
Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662.
4
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.CNVkit:通过靶向DNA测序进行全基因组拷贝数检测与可视化
PLoS Comput Biol. 2016 Apr 21;12(4):e1004873. doi: 10.1371/journal.pcbi.1004873. eCollection 2016 Apr.
5
Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.SMAD4在胰腺癌中的预后价值:一项荟萃分析。
Transl Oncol. 2016 Feb;9(1):1-7. doi: 10.1016/j.tranon.2015.11.007. Epub 2016 Jan 23.
6
Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.拷贝数变化的不同方面:永久的、短暂的和适应性的。
Mol Cell Biol. 2016 Jan 11;36(7):1050-63. doi: 10.1128/MCB.00652-15.
7
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.具有形态学上明显高级别成分的高分化神经内分泌肿瘤:一条与低分化神经内分泌癌不同的途径。
Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19.
8
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.高级别(世界卫生组织G3级)胰腺神经内分泌肿瘤类别在形态学和生物学上具有异质性,包括高分化和低分化肿瘤。
Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.
9
Genomic landscape of pancreatic neuroendocrine tumors.胰腺神经内分泌肿瘤的基因组图谱
World J Gastroenterol. 2014 Dec 14;20(46):17498-506. doi: 10.3748/wjg.v20.i46.17498.
10
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies.胰腺神经内分泌肿瘤中Ki67指数的计算:四种计数方法的比较分析。
Mod Pathol. 2015 May;28(5):686-94. doi: 10.1038/modpathol.2014.156. Epub 2014 Nov 21.

伴有高级别进展的高分化胰腺神经内分泌肿瘤中的位点特异性基因组改变

Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.

作者信息

Martin David R, LaBauve Elisa, Pomo Joseph M, Chiu Vi K, Hanson Joshua A, Gullapalli Rama R

出版信息

Pancreas. 2018 Apr;47(4):502-510. doi: 10.1097/MPA.0000000000001030.

DOI:10.1097/MPA.0000000000001030
PMID:29521944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5884111/
Abstract

The major categories of pancreatic neuroendocrine tumor (PanNET) are well-differentiated NET and poorly differentiated neuroendocrine carcinoma. Sequencing of these tumors has identified multiple important genes in the pathogenesis of PanNETs, such as DAXX/ATRX, MEN1, TP53, RB, and mTOR pathway genes. We identified a case of well-differentiated PanNET with high-grade progression with simultaneous low- and high-grade histologic regions containing variable genomic profiles. We performed tumor microdissection and analyzed both regions using a 409-gene comprehensive cancer panel using next-generation sequencing in addition to immunohistochemical and morphologic studies. The low-grade region showed a change in the DAXX gene as a copy number variant (CNV) deletion. The high-grade region showed CNV deletion changes in the DAXX gene as well as the MEN1 gene. We observed additional mutational changes in the PTEN gene and SMAD4 gene in the high-grade region. Our data support that high-grade progression in PanNETs may be the result of the progressive accumulation of genetic changes (CNVs and point mutational changes) within the body of the tumor. Next generation sequencing may provide pathologists and clinicians with ancillary information to accurately characterize and treat these tumors.

摘要

胰腺神经内分泌肿瘤(PanNET)的主要类别为高分化神经内分泌肿瘤(NET)和低分化神经内分泌癌。对这些肿瘤进行测序已确定了PanNET发病机制中的多个重要基因,如DAXX/ATRX、MEN1、TP53、RB和mTOR通路基因。我们发现了一例高分化PanNET伴有高级别进展,其同时存在低级别和高级别组织学区域,且包含不同的基因组图谱。我们进行了肿瘤微切割,并除免疫组化和形态学研究外,使用下一代测序技术通过一个包含409个基因的综合癌症检测板对两个区域进行了分析。低级别区域显示DAXX基因存在拷贝数变异(CNV)缺失改变。高级别区域显示DAXX基因以及MEN1基因存在CNV缺失改变。我们在高级别区域观察到PTEN基因和SMAD4基因存在额外的突变改变。我们的数据支持PanNET的高级别进展可能是肿瘤体内遗传改变(CNV和点突变改变)逐渐积累的结果。下一代测序可为病理学家和临床医生提供辅助信息,以准确地对这些肿瘤进行特征描述和治疗。